• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

    10/4/24 4:15:02 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVKD alert in real time by email
    SC 13G 1 ea0216479-13ghavlic_cadrenal.htm SCHEDULE 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.      )*

     

    Cadrenal Therapeutics, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    127636207

     

    (CUSIP Number)

     

    September 20, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Havlickova 648 a.s.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Czech Republic

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    66,332

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    66,332

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    66,332

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.2%

    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Dubnica Property s.r.o.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Czech Republic

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    66,332

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    66,332

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    66,332

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.2%

    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 4 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Miroslav Dornak

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Czech Republic

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    66,332

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    66,332

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    66,332

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.2%

    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

     

    Cadrenal Therapeutics, Inc. (the “Issuer”)

     

    Item 1.(b) Address of Issuer’s Principal Executive Offices

     

    822 A1A North, Suite 306

    Ponte Vedra, Florida 32082

     

    Item 2.(a) Names of Person Filing:

     

    Havlickova 648 a.s.

    Dubnica Property s.r.o.

    Miroslav Dornak

    Collectively, the “Reporting Persons”

     

    Item 2.(b) Address of Principal Business Office or, if None, Residence:

     

    Havlickova 648 a.s.

    U Rustonky 714/1

    186 00, Prague

    Czech Republic

     

    Dubnica Property s.r.o.

    U Rustonky 714/1

    186 00, Prague

    Czech Republic

     

    Miroslav Dornak

    U Rustonky 714/1

    186 00, Prague

    Czech Republic

     

    Item 2.(c) Citizenship:

     

    Havlickova 648 a.s. – Czech Republic

     

    Dubnica Property s.r.o. – Czech Republic

     

    Miroslav Dornak – Czech Republic

     

    Item 2.(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Shares”)

     

    Item 2.(e) CUSIP Number:

     

    127636207

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 6 of 9 Pages

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ☐ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned as of October 3, 2024:

     

    Havlickova 648 a.s. – 66,332

     

    Dubnica Property s.r.o. – 66,332

     

    Miroslav Dornak – 66,332

     

    (b)Percent of Class as of October 3, 2024:

     

    Havlickova 648 a.s. – 6.2%

     

    Dubnica Property s.r.o. – 6.2%

     

    Miroslav Dornak – 6.2%

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

     

    Havlickova 648 a.s. – 0

     

    Dubnica Property s.r.o. – 0

     

    Miroslav Dornak – 0

     

    (ii)Shared power to vote or to direct the vote:

     

    Havlickova 648 a.s. – 66,332

     

    Dubnica Property s.r.o. – 66,332

     

    Miroslav Dornak – 66,332

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 7 of 9 Pages

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    Havlickova 648 a.s. – 0

     

    Dubnica Property s.r.o. – 0

     

    Miroslav Dornak – 0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    Havlickova 648 a.s. – 66,332

     

    Dubnica Property s.r.o. – 66,332

     

    Miroslav Dornak – 66,332

     

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 1,067,231 Shares of the Issuer outstanding as of August 20, 2024, based on information reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024, as well as based on information reported on the Issuer’s Form 8-K filed with the SEC on August 20, 2024 regarding the Issuer’s 1-for-15 reverse stock split.

     

    Havlickova 648 a.s. directly holds 66,332 Shares of the Issuer. Dubnica Property s.r.o. is the direct parent of Havlickova 648 a.s. and controls the voting and dispositive power of the 66,332 Shares of the Issuer held by Havlickova 648 a.s. Miroslav Dornak also controls the voting and dispositive power of the 66,332 Shares of the Issuer held by Havlickova 648 a.s. Accordingly, the Reporting Persons are treated as beneficially owning all of the 66,332 Shares of the Issuer directly held by Havlickova 648 a.s.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 127636207 SCHEDULE 13G Page 8 of 9 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 4, 2024

     

      Havlickova 648 a.s.
       
      By:  /s/ Miroslav Dornak
        Miroslav Dornak
        Authorized Signatory
       
      Dubnica Property s.r.o.
       
      By: /s/ Miroslav Dornak
        Miroslav Dornak
        Authorized Signatory
         
      By: /s/ Cyril Florent Vladimir Dejanovski
        Cyril Florent Vladimir Dejanovski
        Authorized Signatory
         
      By: /s/ Miroslav Dornak
        Miroslav Dornak

     

     

     

      

    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning such person contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that such person knows or has reason to believe that such information is inaccurate.

     

    Dated: October 4, 2024

     

      Havlickova 648 a.s.
       
      By: /s/ Miroslav Dornak
        Miroslav Dornak
        Authorized Signatory
       
      Dubnica Property s.r.o.
       
      By: /s/ Miroslav Dornak
        Miroslav Dornak
        Authorized Signatory
         
      By: /s/ Cyril Florent Vladimir Dejanovski
        Cyril Florent Vladimir Dejanovski
        Authorized Signatory
         
      By: /s/ Miroslav Dornak
        Miroslav Dornak

     

     

     

     

     

    Get the next $CVKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVKD

    DatePrice TargetRatingAnalyst
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $CVKD
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

      James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

      2/6/25 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

      Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

      12/18/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

      PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

      2/8/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

      Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

      12/18/23 8:12:12 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CEO and Chairman Pham Quang X

      4/A - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      3/24/25 8:38:14 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ferguson James J. Iii

      4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:51:35 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Ferguson James J. Iii

      3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:50:29 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    SEC Filings

    See more
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 4:05:33 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cadrenal Therapeutics Inc.

      10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 6:17:43 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      4/17/25 6:12:02 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

      LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patie

      6/12/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company's strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at cadrena

      6/4/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy. Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently und

      5/15/25 7:30:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Financials

    Live finance-specific insights

    See more
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

      SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      11/14/24 4:00:17 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

      SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      10/4/24 4:15:02 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care